Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

Tirzepatide was first approved by the Food and Drug Administration ... only options when it comes to weight loss or diabetes, and signficantly more affordable FDA-approved options do exist.

These medications have been associated with a 40 percent reduction in opioid overdose and 50 percent lower rate of alcohol intoxication.

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

(The Hill) – Federal regulators shook up the booming weight loss drug marketplace ... Tirzepatide was first approved by the Food and Drug Administration (FDA) in 2022 and has no generic versions ...